Orthofix Medical (OFIX) Issues FY18 Earnings Guidance

Share on StockTwits

Orthofix Medical (NASDAQ:OFIX) issued an update on its FY18 earnings guidance on Monday morning. The company provided EPS guidance of $1.70-1.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.68. Orthofix Medical also updated its FY 2018 guidance to $1.70-1.75 EPS.

NASDAQ OFIX traded up $4.55 on Tuesday, reaching $61.18. The company had a trading volume of 20,072 shares, compared to its average volume of 145,146. The firm has a market capitalization of $1.06 billion, a P/E ratio of 37.65, a PEG ratio of 3.46 and a beta of 0.36. Orthofix Medical has a 52-week low of $48.30 and a 52-week high of $61.98.

Orthofix Medical (NASDAQ:OFIX) last released its quarterly earnings results on Monday, October 29th. The medical device company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.16. The business had revenue of $111.70 million during the quarter, compared to analyst estimates of $110.65 million. Orthofix Medical had a return on equity of 10.74% and a net margin of 2.53%. Orthofix Medical’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.42 EPS. As a group, research analysts anticipate that Orthofix Medical will post 1.68 EPS for the current fiscal year.

OFIX has been the subject of several research analyst reports. Zacks Investment Research raised Orthofix Medical from a strong sell rating to a hold rating in a research report on Wednesday, July 4th. BidaskClub lowered Orthofix Medical from a strong-buy rating to a buy rating in a research report on Tuesday, July 31st. TheStreet raised Orthofix Medical from a c+ rating to a b- rating in a research report on Monday, September 10th. Finally, Cantor Fitzgerald raised their target price on Orthofix Medical to $66.00 and gave the company an overweight rating in a research report on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Buy and an average price target of $62.25.

In other news, CFO Rice Doug sold 3,949 shares of the stock in a transaction on Thursday, October 11th. The stock was sold at an average price of $55.65, for a total transaction of $219,761.85. Following the completion of the transaction, the chief financial officer now owns 32,368 shares in the company, valued at approximately $1,801,279.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brad Mason sold 2,500 shares of the stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $53.02, for a total value of $132,550.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,949 shares of company stock valued at $485,487 in the last quarter. 5.60% of the stock is owned by corporate insiders.

About Orthofix Medical

Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures.

Featured Story: Tariff

Earnings History and Estimates for Orthofix Medical (NASDAQ:OFIX)

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply